Articles of Interest [Archive] - HER2 Support Group Forums

What Should You Buy Custom Trucker Caps? (0 replies)
Developing Leadership Skills in Nursing (1 replies)
Academic Boost: Leading Online Assignment Services (2 replies)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy (1 replies)
How Much Do Our Thoughts Shape Our Health? (1 replies)
Optimal Sequential Strategies for antibody drug conjugate (0 replies)
Breast cancer highlights from 2023 - Advanced breast cancer in 2023 (0 replies)
Targeting Breast Cancer: An Overlook on Current Strategies (0 replies)
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer (0 replies)
Next-Generation HER2-Targeted Antibody?Drug Conjugates in Breast Cancer (0 replies)
Immunotherapy in breast cancer: an overview of current strategies and perspectives (0 replies)
Anticipating changes in the HER2 status of breast tumours with disease ... (0 replies)
Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays (0 replies)
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets (0 replies)
All Relevant Subgroups With ESR1-Mutant MBC Derive PFS Benefit With Elacestrant (0 replies)
GATA3 mediates doxorubicin resistance ... (0 replies)
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatmen (0 replies)
A Phase I/II Trial of HER2 Vaccine–Primed ...Treatment Refractory HER2–Overexpressing (0 replies)
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy? (0 replies)
A review of treatment options in HER2-low breast cancer and proposed treatment sequen (0 replies)
Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term ... (0 replies)
Estradiol as treatment for ER+ breast cancer. (0 replies)
CEA marker bone met (0 replies)
The State of the Union in Cancer Innovation (0 replies)
ARX788 possible new drug after t-dm1, t-dxd, tucatinib (0 replies)
A couple of articles on metronomic therapy (0 replies)
long term comparing IV vs subcutaneous trastuzumab (0 replies)
Diclofenac for treatment of neuropathy from Capecitabine (Xeloda) (0 replies)
Nature itself is the best physician (0 replies)
Upping levels of key nutrient maintains immune cell response to cancer (0 replies)
Genomic Assay Changes Minds on HER2+ Breast Cancer Treatment (0 replies)
Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disord (0 replies)
‘Chemo brain’ is real, but there are ways to ease it (0 replies)
Use of Alternative Medicine for Cancer and Its Impact on Survival (0 replies)
Impact of Antibiotic Exposure ... Checkpoint Inhibitor Treatment (0 replies)
Identifying the optimal therapeutics ... ER+ & Her2+ (0 replies)
Clinical utility of liquid biopsy in breast cancer: A systematic review (0 replies)
Brain-Thought-Cancer-Sick (0 replies)
Free mobile application from the American Society of Clinical Oncology. (0 replies)
How I treat HER2-low advanced breast cancer (0 replies)
Cancer vaccines are already a reality—but your doctor might ... (0 replies)
Datopotamab deruxtecan ... durable efficacy in patients with heavily pretreated (0 replies)
Paxlovid and other covid treatments. (0 replies)
Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastroz (0 replies)
What Clinicians Want to Know: Addressing Current Questions and Controversies in the M (0 replies)
Promotion of hair growth by Rosmarinus officinalis leaf extract (0 replies)
Asco 2022 breast cancer research summary (0 replies)
Warning: Popular Vitamin Supplement Causes Cancer Risk and Brain Metastasis (0 replies)
CRISPR cancer trial success paves the way for personalized treatments (0 replies)
Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Surviv (0 replies)
Application of HER2 peptide vaccines in patients with breast cancer: a systematic rev (0 replies)
Effects of weight-lifting or resistance exercise on breast cancer-related lymphedema: (0 replies)
Cancer Center Announces First Patient Has Received City of Hope’s Novel, Potentially (0 replies)
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures (0 replies)
Switch to Fulvestrant and Palbociclib vs No Switch in Advanced Breast Cancer With Ris (0 replies)
Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive (0 replies)
Precision medicine improves outcomes in metastatic breast cancer (1 replies)
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q (0 replies)
Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus t (0 replies)
Amcenestrant in Endocrine-Resistant ER+/HER2− Advanced Breast Cancer (0 replies)
Enhertu and interstitial lung disease (0 replies)
If you are looking for Evusheld (covid prophylactic) (2 replies)
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA t (0 replies)
Plant-Based and Ketogenic Diets As Diverging Paths to Address Cancer A Review (0 replies)
Clinical implications of prospective genomic profiling of metastatic breast cancer pa (0 replies)
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update (0 replies)
Optimal timing and interval of imaging for metastatic breast cancer. (0 replies)
Use of real-world data ...circulating tumor DNA (cfDNA) in identifying resistance (0 replies)
A couple of informative articles on management of ER+ MBC (0 replies)
Exercise Recommendation for People With Bone Metastases (1 replies)
BC vaccine from your own tumor (0 replies)
Enhertu additional analyses ...metastatic breast cancer (0 replies)
Assessment of a cancer genomic profile test for patients with metastatic breast cance (0 replies)
Emerging new therapeutic antibody derivatives for cancer treatment (0 replies)
Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective (0 replies)
IL-6 Is Biomarker for Distant Recurrence of Stage II/III Breast Cancer (0 replies)
Enhertu tightens its stranglehold (0 replies)
Treatment Switch After ESR1 Mutation Detected Shows Benefit (0 replies)
NIH study advances personalized immunotherapy for metastatic breast cancer (0 replies)
Current and future landscape of targeted therapy in HER2-positive advanced breastcanc (0 replies)
The Exciting New Field of HER2-Low Breast Cancer Treatment (0 replies)
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibiti (0 replies)
covid infection and cancer patients ... (8 replies)
Aiming at a Tailored Cure for ERBB2 Positive Metastatic Breast Cancer:A Review (0 replies)
Elacestrant Shines in EMERALD Trial (1 replies)
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy (0 replies)
New cancer treatment may reawaken the immune system (0 replies)
BioNTech mRNA Cancer Treatment Moved To Human Trials After Huge Success In Mice (0 replies)
Assessing Biomarkers in Metastatic Breast Cancer (0 replies)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase (0 replies)
Expert Discussion: HER2-Positive Breast Cancer (0 replies)
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Pa (0 replies)
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-posi (0 replies)
SYD985 /trastuzumab duocarmazine (0 replies)
Advocating for Patients (0 replies)
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast canc (0 replies)
The emerging role of CDK4/6i in HER2-positive breast cancer (0 replies)
Current and Future Management of HER2-Positive Metastatic Breast Cancer (0 replies)
Perlmutter Cancer Center Researchers Find Breast Cancer Treatments Do Not Increase Ri (0 replies)
Implementation of Precision Oncology for Patients withMetastatic Breast Cancer in an (0 replies)
efficacy data about covid vaccine for high risk populations. (3 replies)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Ad (0 replies)
Treatment strategies for breast cancer brain metastases (0 replies)
Phenotypic changes of HER2-positive breast cancerduring and after dual HER2 blockade (0 replies)
Wire-Free Localization Technology for Breast Cancer Surgery (0 replies)
weight-based IV dosing of trastuzumab vs SC fixed-dose (0 replies)
Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors (0 replies)
Tumor tissue- versus plasma-based genotyping for selection of matched therapy (0 replies)
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestra (0 replies)
CDK 4/6 Inhibitors Are Associated With a High Incidence of Thrombotic Events in Breas (1 replies)
Targeting a neoantigen derived from a common TP53 mutation (0 replies)
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tum (0 replies)
Androgens show new compelling evidence of anti-tumor activity (0 replies)
Off topic:caring for healthcare professionals (1 replies)
Cytotoxic T-cells mediate exercise-induced reductions in tumor growth (0 replies)
Covid vaccines and cancer patients (20 replies)
Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatmen (1 replies)
The FDA has approved margetuximab-cmkb (0 replies)
Complementary and integrative medicine for breast cancer patients - Evidence based pr (0 replies)
Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer ... (0 replies)
Genomic alterations in breast cancer: level ofevidence for actionability (0 replies)
Psilocybin produces substantial and sustained decreases in depression and anxiety in (0 replies)
Letter to a friend who was recently diagnosed with BC. (2 replies)
Heart health monitor: LVEF vs GLS (0 replies)
Clinical implications of prospectivegenomic profiling of metastatic breastcancer pati (0 replies)
Novel targeted therapies for metastatic breast cancer (0 replies)
Breast cancer and covid (0 replies)
This scientist made a Google Doc to educate the public about airborne coronavirus tra (0 replies)
First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor Positive Ear (0 replies)
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profilin (0 replies)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (0 replies)
“…evaluating palbociclib (CDK4/6) treatment outcome …” (0 replies)
Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors... (0 replies)
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inh (4 replies)
CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought (0 replies)
Combination Strategies ...Immunotherapy (0 replies)
Six distinct "types" of COVID-19 identified (0 replies)
Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach (0 replies)
Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Canc (0 replies)
Risk of early progression according to circulating ESR1 mutation... (0 replies)
Hopefully this will be another weapon for us in the fight. (0 replies)
Cardiac monitoring in HER2-positive patients (0 replies)
6/2020:American Cancer Society Guideline for Diet and Physical Activity for cancer pr (0 replies)
A couple of articles on current immunotherapy for her2 positive BC (0 replies)
Tucatinib aka ONT-380 (0 replies)
Treatment After Progression on CDK 4/6i in mBC (2 replies)
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the P (0 replies)
Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets (0 replies)
Discordance in ER/PR/Her2 ; Imaging to detect Hormone Receptor (0 replies)
Vision problems due to anastrozole, bisphosphonate, or ??? (0 replies)
Perhaps something we can do in case we can't get treatment for covid-19. (3 replies)
A few words about N95 respirator (2 replies)
In case you are making a mask. (1 replies)
A few Covid-19 and cancer articles (1 replies)
Personalized Detection of Circulating Tumor DNAAntedates Breast Cancer Metastatic Rec (0 replies)
Efficacy and Safety of Nab-Paclitaxel Compared With Solvent-Based Taxanes for Metasta (0 replies)
Psilocybin produces substantial and sustained decreases in depression and anxiety in (0 replies)
Over come resistance to Neratinib with Affinitor. (0 replies)
Molecular profiling for precision cancer therapies (0 replies)
T-DM1–Associated Cardiotoxicity in Advanced HER2-Positive Breast Cancer (0 replies)
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade (0 replies)
Discovering the anticancer potential of non-oncology drugs by systematic viability pr (0 replies)
Is anyone familiar with using Noscapine for breast cancer treatment? (6 replies)
Combating subclonal evolution of resistant cancer phenotypes (0 replies)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Re (0 replies)
Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer (0 replies)
Monitoring Tumor-Specific Mutations in Early-Stage Breast Cancer With ctDNA (0 replies)
Molecular imaging to identify patients with benefit...endocrine treatment combined... (0 replies)
Nutrient-wide association study of 92 foods and nutrients and breast cancer risk (0 replies)
Using Essential Oils for Aromatherapy (0 replies)
Complementary therapies can do more harm than good when breast cancer becomes visible (0 replies)
Behind the Scenes of a Radical New Cancer "Cure" (0 replies)
CRISPR Approach To Fighting Cancer Called 'Promising' In 1st Safety Test (0 replies)
Palbociclib and Letrozole and zearalenone and genistein (0 replies)
A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-target (0 replies)
Stress and cancer metastasis (0 replies)
Blood Test May Be Able To Predict Breast Cancer Relapse (0 replies)
Mindfulness‐based cancer recovery and supportive‐expressive therapy maintain telomere (1 replies)
Multiple modes of action of eribulin mesylate: Emerging data and clinical implication (0 replies)
Broccoli Is Dying. Corn Is Toxic. Long Live Microbiomes! (1 replies)
Abscopal effect of radiotherapy (0 replies)
Why mouse models fail. (2 replies)
Radical New Approach to Cancer Drug Use (0 replies)
The Fasting Cure Is No Fad (2 replies)
Association between HER2 positivity by HER2/CEP17 ratio (0 replies)
Patients Liable to Be Misclassified Under New HER2 Gene Testing Guidelines, Expert Sa (0 replies)
High fruit and vegetable consumption may reduce risk of breast cancer, especially agg (0 replies)
Manage Diarrhea in Patients Receiving Nerlynx® (Neratinib) (0 replies)
metronomic eribulin (0 replies)
Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do (1 replies)
Targeted Agent and Profiling Utilization Registry (TAPUR) (0 replies)
The Promise and Price of Cellular Therapies (1 replies)
Biomarkers for Immunotherapy: Current Developments andChallenges (0 replies)
Neratinib versus Tucatinib (0 replies)
Novel Agents May Challenge Standard Therapy in Advanced HER2+ Breast Cancer (0 replies)
Chemotherapy principles of managing stage IV breast cancer in the United States (0 replies)
Redrawing the Lines: The Next Generation ofTreatment in Metastatic Breast Cancer (0 replies)
Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells (1 replies)
Immunotherapy for HER2-positive breast cancer: recent advances and combination therap (0 replies)
Combination of Natural Agent with Synthetic Drug for the Breast Cancer Therapy (0 replies)
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (2 replies)
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance (0 replies)
Amplification v.s Mutation (0 replies)
Specially created animal 'cancer avatars' could personalise treatments (0 replies)
MacroGenics Announces Positive Results from Phase 3 SOPHIA of Margetuximab (0 replies)
Cryotherapy for neuropathy. (0 replies)
Breast Cancer Epidemiology and Prevention (0 replies)
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer (0 replies)
VACCINE STUDY FOR HER2-POSITIVE BREAST CANCER MOVES FORWARD Volume 8, Issue 1, March (0 replies)
Why It Can Take So Long to Get Cancer Drugs (0 replies)
A Clever New Strategy for Treating Cancer, Thanks to Darwin (0 replies)
Cancer Patients Are Getting Robotic Surgery. There’s No Evidence It’s Better. (0 replies)
Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce (0 replies)
Immune recognition of somatic mutations leading to complete durable regression in met (0 replies)
HER2-Positive Breast Cancer and Resistance: What Next? (0 replies)
MacroGenics’ margetuximab beats Herceptin in phase 3 (1 replies)
New treatment for Alzheimer’s & potential uses for BC (0 replies)
Anti-tumor DaRT could point the way to new arsenal in battle against cancer (0 replies)
self-reported diet during treatment and chemotherapy-induced peripheral neuropathy (1 replies)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cel (0 replies)
Organic Foods for Cancer Prevention—Worth the Investment? (0 replies)
We can now customize cancer treatments, tumor by tumor (0 replies)
Emerging Treatments for HER2+ and Mutant Breast Cancer (0 replies)
Optimizing HER2-Targeted Therapy (0 replies)
Some potential new drugs. (0 replies)
Immunotherapy for MBC (0 replies)
Less Herceptin? (7 replies)
A study of how bc metastasizes (0 replies)
Tumor Organoids Predict How Well Patients Respond to Cancer Drugs (0 replies)
New Lymphadema tx (0 replies)
Not all false positives from imaging are the same (0 replies)
If you ever develop heart failure, mention treatment (0 replies)
Her2 is not a cancer subtype, but a Pan Cancer Event (2 replies)
Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy (0 replies)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (1 replies)
Onco test (0 replies)
Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer (0 replies)
how ironic (0 replies)
cancer-researchers-worry-about-potential-downsides-of-immunotherapy (3 replies)
current-standards-and-new-tratment-insights-in-her2-driven-metastatic-breast-disease (0 replies)
A educational video about one future of individualize immunotherapy (0 replies)
Familial cancer (0 replies)
How Breast Cancer Can Spread Before a Tumor Develops (2 replies)
Glucose and the development of bc (0 replies)
Accurate Predictors of Response to Endocrine Therapy (0 replies)
Breast Microbiome May Play a Role in Breast Cancer (0 replies)
Basis for some Herceptin related heart SE's (0 replies)
Study: Cancer center ads are costly, manipulative (0 replies)
Learning From the Lazarus Effect (0 replies)
UK Trial shows promising results for early lapatinib + herceptin (2 replies)